Journal Logo

CE Connection

New Drugs 2018, part 1

Author Information
doi: 10.1097/01.NURSE.0000530373.15863.80
  • Free

INSTRUCTIONS New Drugs 2018, part 1


  • To take the test online, go to our secure website at View instructions for taking the test online there.
  • If you prefer to submit your test by mail, record your answers in the test answer section of the CE enrollment form on page 45. You may make copies of the form. Each question has only one correct answer. There is no minimum passing score required.
  • Complete the registration information and course evaluation. Mail the completed form and registration fee of $17.95 to: Lippincott Professional Development, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
  • You will receive your CE certificate of earned contact hours and an answer key to review your results.
  • Registration deadline is February 29, 2020.


  • Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together by mail, and deduct $0.95 from the price of each test.
  • We also offer CE accounts for hospitals and other healthcare facilities on Call 1-800-787-8985 for details.


Lippincott Professional Development will award 1.5 contact hours for this continuing nursing education activity.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida CE Broker #50-1223. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours. This activity has been assigned 1.5 pharmacology credits.

New Drugs 2018, part 1

PURPOSE: To provide information on seven drugs newly approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe the indications for seven newly approved drugs. 2. Identify nursing implications for these new drugs.

  1. Bezlotoxumab is indicated in adults
    1. to treat CDI.
    2. to reduce CDI recurrence.
    3. as an alternative to vancomycin for treating CDI.
  2. Bezlotoxumab should be used with caution for patients with a history of
    1. heart failure.
    2. hypertension.
    3. type 1 diabetes.
  3. When administering bezlotoxumab, the nurse should
    1. discard any unused solution stored at room temperature for over 8 hours.
    2. use a 0.2 to 5 micron in-line or add-on filter.
    3. protect the I.V. container from light.
  4. Sofosbuvir/velpatasvir/voxilaprevir is not recommended for concurrent use with
    1. betrixaban.
    2. ampicillin.
    3. amiodarone.
  5. Sofosbuvir/velpatasvir/voxilaprevir is not recommended for use in patients with
    1. moderate hepatic impairment.
    2. renal insufficiency.
    3. thyroid dysfunction.
  6. The recommended dosage for sofosbuvir/velpatasvir/voxilaprevir is one tablet
    1. twice a day for 6 weeks.
    2. once a day for 12 weeks.
    3. once a day for 8 weeks.
  7. The most common adverse reactions to sofosbuvir/velpatasvir/voxilaprevir include
    1. tachycardia.
    2. tinnitus.
    3. diarrhea.
  8. The recommended duration of treatment for treatment-naive patients without cirrhosis taking glecaprevir/pibrentasvir is
    1. 8 weeks.
    2. 12 weeks.
    3. 16 weeks.
  9. Which of the following is not a contraindication for treatment with glecaprevir/pibrentasvir?
    1. severe hepatic impairment
    2. chronic HCV genotype 1 infection
    3. concurrent therapy with atazanavir
  10. Betrixaban is indicated to treat
    1. intracranial hemorrhage.
    2. constipation.
    3. venous thromboembolism.
  11. Betrixaban is classified as a
    1. vitamin K antagonist.
    2. direct factor Xa inhibitor.
    3. direct thrombin inhibitor.
  12. The initial single daily dose of betrixaban is
    1. 40 mg.
    2. 80 mg.
    3. 160 mg.
  13. Plecanatide is contraindicated for patients
    1. under age 6.
    2. with hypertension.
    3. with hypoglycemia.
  14. Teach patients to store plecanatide in its original container
    1. with the polyester coil in place.
    2. with the desiccant in place.
    3. in the refrigerator.
  15. Naldemedine is indicated for adults with chronic noncancer pain with
    1. Crohn disease.
    2. peptic ulcer disease.
    3. opioid-induced constipation.
  16. Which is correct about naldemedine?
    1. Patients should take each dose on an empty stomach.
    2. It's currently classified by the FDA as a Schedule II controlled substance.
    3. It should be discontinued if treatment with the opioid analgesic is discontinued.
  17. Edaravone is administered
    1. orally.
    2. via I.V. infusion.
    3. subcutaneously.
  18. Which is correct about edaravone?
    1. It prolongs survival in patients with ALS.
    2. It should be administered within 12 hours after opening the overwrap package.
    3. It should be protected from light.
Wolters Kluwer Health, Inc. All rights reserved